Cargando…
Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14)
BACKGROUND: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532501/ https://www.ncbi.nlm.nih.gov/pubmed/23300888 http://dx.doi.org/10.1371/journal.pone.0053188 |
_version_ | 1782254320499032064 |
---|---|
author | Allen, George E. Brown, Simon G. A. Buckley, Nicholas A. O’Leary, Margaret A. Page, Colin B. Currie, Bart J. White, Julian Isbister, Geoffrey K. |
author_facet | Allen, George E. Brown, Simon G. A. Buckley, Nicholas A. O’Leary, Margaret A. Page, Colin B. Currie, Bart J. White, Julian Isbister, Geoffrey K. |
author_sort | Allen, George E. |
collection | PubMed |
description | BACKGROUND: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical and laboratory features of definite brown snake (Pseudonaja spp.) envenoming, and determine the dose of antivenom required. METHODS AND FINDING: This was a prospective observational study of definite brown snake envenoming from the Australian Snakebite Project (ASP) based on snake identification or specific enzyme immunoassay for Pseudonaja venom. From January 2004 to January 2012 there were 149 definite brown snake bites [median age 42y (2–81y); 100 males]. Systemic envenoming occurred in 136 (88%) cases. All envenomed patients developed venom induced consumption coagulopathy (VICC), with complete VICC in 109 (80%) and partial VICC in 27 (20%). Systemic symptoms occurred in 61 (45%) and mild neurotoxicity in 2 (1%). Myotoxicity did not occur. Severe envenoming occurred in 51 patients (38%) and was characterised by collapse or hypotension (37), thrombotic microangiopathy (15), major haemorrhage (5), cardiac arrest (7) and death (6). The median peak venom concentration in 118 envenomed patients was 1.6 ng/mL (Range: 0.15–210 ng/mL). The median initial antivenom dose was 2 vials (Range: 1–40) in 128 patients receiving antivenom. There was no difference in INR recovery or clinical outcome between patients receiving one or more than one vial of antivenom. Free venom was not detected in 112/115 patients post-antivenom with only low concentrations (0.4 to 0.9 ng/ml) in three patients. CONCLUSIONS: Envenoming by brown snakes causes VICC and over a third of patients had serious complications including major haemorrhage, collapse and microangiopathy. The results of this study support accumulating evidence that giving more than one vial of antivenom is unnecessary in brown snake envenoming. |
format | Online Article Text |
id | pubmed-3532501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-35325012013-01-08 Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) Allen, George E. Brown, Simon G. A. Buckley, Nicholas A. O’Leary, Margaret A. Page, Colin B. Currie, Bart J. White, Julian Isbister, Geoffrey K. PLoS One Research Article BACKGROUND: Snakebite is a global health issue and treatment with antivenom continues to be problematic. Brown snakes (genus Pseudonaja) are the most medically important group of Australian snakes and there is controversy over the dose of brown snake antivenom. We aimed to investigate the clinical and laboratory features of definite brown snake (Pseudonaja spp.) envenoming, and determine the dose of antivenom required. METHODS AND FINDING: This was a prospective observational study of definite brown snake envenoming from the Australian Snakebite Project (ASP) based on snake identification or specific enzyme immunoassay for Pseudonaja venom. From January 2004 to January 2012 there were 149 definite brown snake bites [median age 42y (2–81y); 100 males]. Systemic envenoming occurred in 136 (88%) cases. All envenomed patients developed venom induced consumption coagulopathy (VICC), with complete VICC in 109 (80%) and partial VICC in 27 (20%). Systemic symptoms occurred in 61 (45%) and mild neurotoxicity in 2 (1%). Myotoxicity did not occur. Severe envenoming occurred in 51 patients (38%) and was characterised by collapse or hypotension (37), thrombotic microangiopathy (15), major haemorrhage (5), cardiac arrest (7) and death (6). The median peak venom concentration in 118 envenomed patients was 1.6 ng/mL (Range: 0.15–210 ng/mL). The median initial antivenom dose was 2 vials (Range: 1–40) in 128 patients receiving antivenom. There was no difference in INR recovery or clinical outcome between patients receiving one or more than one vial of antivenom. Free venom was not detected in 112/115 patients post-antivenom with only low concentrations (0.4 to 0.9 ng/ml) in three patients. CONCLUSIONS: Envenoming by brown snakes causes VICC and over a third of patients had serious complications including major haemorrhage, collapse and microangiopathy. The results of this study support accumulating evidence that giving more than one vial of antivenom is unnecessary in brown snake envenoming. Public Library of Science 2012-12-28 /pmc/articles/PMC3532501/ /pubmed/23300888 http://dx.doi.org/10.1371/journal.pone.0053188 Text en © 2012 Allen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Allen, George E. Brown, Simon G. A. Buckley, Nicholas A. O’Leary, Margaret A. Page, Colin B. Currie, Bart J. White, Julian Isbister, Geoffrey K. Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) |
title | Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) |
title_full | Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) |
title_fullStr | Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) |
title_full_unstemmed | Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) |
title_short | Clinical Effects and Antivenom Dosing in Brown Snake (Pseudonaja spp.) Envenoming — Australian Snakebite Project (ASP-14) |
title_sort | clinical effects and antivenom dosing in brown snake (pseudonaja spp.) envenoming — australian snakebite project (asp-14) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532501/ https://www.ncbi.nlm.nih.gov/pubmed/23300888 http://dx.doi.org/10.1371/journal.pone.0053188 |
work_keys_str_mv | AT allengeorgee clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT brownsimonga clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT buckleynicholasa clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT olearymargareta clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT pagecolinb clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT curriebartj clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT whitejulian clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT isbistergeoffreyk clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 AT clinicaleffectsandantivenomdosinginbrownsnakepseudonajasppenvenomingaustraliansnakebiteprojectasp14 |